Navigation Links
LSUHSC researcher awarded NCI grant to study link between chronic inflammation and cancer
Date:7/18/2013

New Orleans, LA Yan Cui, PhD, Associate Professor of Microbiology, Immunology, & Parasitology at LSU Health Sciences Center New Orleans and the LSUHSC Stanley S. Scott Cancer Center, has been awarded a $1.5 million grant over five years by the National Cancer Institute to study the role of chronic inflammation in the development and progression of cancer.

Tumor suppressor protein 53, or p53, is a crucial molecule that is known to prevent cancer by either directly killing cancer cells or by stopping cancer cells from multiplying. The loss of p53 function resulting from genetic changes is detected in 50% of tumors and is considered to be one of the leading causes of cancer. However, p53 dysfunction caused by these mutations can also occur in normal cells surrounding the cancer cells, called stromal cells, and mutations in the p53 gene in some of them are associated with increased cancer spread and poor prognosis. According to the National Cancer Institute, a stromal cell is a type of cell that makes up certain types of connective tissue (supporting tissue that surrounds other tissues and organs). When cells become malignant, the surrounding stromal cells also change. So far, it is not entirely clear how these adjacent, normal cells that lack functional p53 affect the growth and replication of cancer cells.

This grant award is based upon published studies performed in Dr. Cui's laboratory, one of which was chronicled as a cover story in the March 15, 2013, issue of Cancer Research.

These studies demonstrated that a lack of functional p53 in tumor-associated stromal cells, as well as some of the immune cells, leads to an inflammatory microenvironment that suppresses the body's immune system to fight the cancer, increases the number of stromal cells infiltrating the tumor, and promotes blood vessel formation to nourish the tumor leading to its accelerated growth.

"These earlier findings broaden our understanding of the importance of this critical tumor suppressor protein as a guardian and gatekeeper for the proper function of patients' immune systems," notes Dr. Cui. "This newly funded project will further investigate whether hindering p53 causes chronic inflammation that creates an environment conducive for cancer formation, growth, and metastasis."

Dr. Cui will collaborate with Augusto Ochoa, MD, Director of the LSUHSC Stanley S. Scott Cancer Center, and Paulo Rodriguez, PhD, an assistant professor at LSU Health Sciences Center New Orleans, both leaders in the field of inflammatory cells and cancer. The long-term goal is to develop new approaches that target the p53 pathway and tumor-associated stromal cells to prevent or advance the treatment of cancer.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC research identifies new risk factors for parasitic infection
2. LSUHSC research discovers new drug target for metastatic breast cancer
3. LSUHSC research identifies co-factors critical to PTSD development
4. LSUHSC scientist awarded nearly $2 million to determine role of biofilms in common fungal infection
5. LSUHSC research discovery provides therapeutic target for ALS
6. LSUHSCs Weiss chosen to help set national eye policy, research
7. LSUHSC research identifies new therapeutic target for Alzheimers disease
8. LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS
9. LSUHSC research finds treating stress prevented new MS brain lesions
10. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
11. Solving DNA puzzles is overwhelming computer systems, researchers warn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, risk ... its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit will ... in Boston, MA. , The Omni Parker House Hotel, which is located at 60 ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, a privately owned ... travel award to noteworthy scientists who will be presenting research using ACEA Biosciences’ ... of awards are being given to two postdoctoral fellows studying pathogen capture by ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural products ... through enhancement of the gut microbiota, today announced the closing of its first round ... York-based Sustainable Income Capital Management, LLC and a number of private investors. The company ...
Breaking Biology Technology: